142 related articles for article (PubMed ID: 24259747)
21. Comparison of anti-Xa and activated partial thromboplastin time monitoring for heparin dosing in patients with cirrhosis.
Fuentes A; Gordon-Burroughs S; Hall JB; Putney DR; Monsour HP
Ther Drug Monit; 2015 Feb; 37(1):40-4. PubMed ID: 24901494
[TBL] [Abstract][Full Text] [Related]
22. Direct Oral Anticoagulants (DOACs) in the Laboratory: 2015 Review.
Adcock DM; Gosselin R
Thromb Res; 2015 Jul; 136(1):7-12. PubMed ID: 25981138
[TBL] [Abstract][Full Text] [Related]
23. A comparative trial of anti-factor Xa levels versus the activated partial thromboplastin time for heparin monitoring.
Vandiver JW; Vondracek TG
Hosp Pract (1995); 2013 Apr; 41(2):16-24. PubMed ID: 23545756
[TBL] [Abstract][Full Text] [Related]
24. Competition of unfractionated heparin and idraparinux on activated partial thromboplastin time and effect of exogenous antithrombin.
Gouin-Thibault I; Samama MM
Thromb Haemost; 2009 May; 101(5):986-7. PubMed ID: 19404557
[No Abstract] [Full Text] [Related]
25. Quantitative measurement of heparin in comparison with conventional anticoagulation monitoring and the risk of thrombotic events in adults on extracorporeal membrane oxygenation.
Chu DC; Abu-Samra AG; Baird GL; Devers C; Sweeney J; Levy MM; Muratore CS; Ventetuolo CE
Intensive Care Med; 2015 Feb; 41(2):369-70. PubMed ID: 25465907
[No Abstract] [Full Text] [Related]
26. Risk factors for major bleeding in patients with heparin-induced thrombocytopenia treated with argatroban: a retrospective study.
Hursting MJ; Verme-Gibboney CN
J Cardiovasc Pharmacol; 2008 Dec; 52(6):561-6. PubMed ID: 19057393
[TBL] [Abstract][Full Text] [Related]
27. Reversal of direct oral anticoagulants.
Cohen O; Frank LA; Bradley S
Br J Hosp Med (Lond); 2018 May; 79(5):C70-C73. PubMed ID: 29727244
[No Abstract] [Full Text] [Related]
28. Argatroban, a new treatment option for heparin-induced thrombocytopenia.
Cleveland KW
Crit Care Nurse; 2003 Dec; 23(6):61-6. PubMed ID: 14692173
[No Abstract] [Full Text] [Related]
29. Effect of therapeutic INR on activated clotting times, heparin dosage, and bleeding risk during ablation of atrial fibrillation.
Gautam S; John RM; Stevenson WG; Jain R; Epstein LM; Tedrow U; Koplan BA; McClennen S; Michaud GF
J Cardiovasc Electrophysiol; 2011 Mar; 22(3):248-54. PubMed ID: 20812929
[TBL] [Abstract][Full Text] [Related]
30. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
[TBL] [Abstract][Full Text] [Related]
31. Direct oral anticoagulants (DOACs).
Vazquez S; Rondina MT
Vasc Med; 2015 Dec; 20(6):575-7. PubMed ID: 26285587
[TBL] [Abstract][Full Text] [Related]
32. An evaluation of four modes of low-dose anticoagulation during intermittent haemodialysis.
Skagerlind MSE; Stegmayr BG
Eur J Clin Pharmacol; 2018 Mar; 74(3):267-274. PubMed ID: 29198062
[TBL] [Abstract][Full Text] [Related]
33. Dabigatran monitoring made simple?
Eikelboom JW; Weitz JI
Thromb Haemost; 2013 Sep; 110(3):393-5. PubMed ID: 23884303
[No Abstract] [Full Text] [Related]
34. Anticoagulation for pediatric mechanical circulatory support.
Annich G; Adachi I
Pediatr Crit Care Med; 2013 Jun; 14(5 Suppl 1):S37-42. PubMed ID: 23735984
[TBL] [Abstract][Full Text] [Related]
35. Coagulation factor abnormalities related to discordance between anti-factor Xa and activated partial thromboplastin time in patients supported with continuous-flow left ventricular assist devices.
Adatya S; Sunny R; Fitzpatrick MJ; Colvin M; Thennapan T; John R; Dodge Zantek N; Pritzker M; Eckman P; Uriel N
J Heart Lung Transplant; 2016 Nov; 35(11):1311-1320. PubMed ID: 27836023
[TBL] [Abstract][Full Text] [Related]
36. Heparin and low-molecular-weight heparin.
Gray E; Mulloy B; Barrowcliffe TW
Thromb Haemost; 2008 May; 99(5):807-18. PubMed ID: 18449410
[TBL] [Abstract][Full Text] [Related]
37. [Comparison of heparin-induced prolongation of APTT in 12 different laboratories in Kyushu area].
Tanaka N; Manabe M; Yamashita S; Ikeda K; Obayashi K; Uchiba M; Ando Y
Rinsho Byori; 2013 Jul; 61(7):576-82. PubMed ID: 24205697
[TBL] [Abstract][Full Text] [Related]
38. Dermatan sulfate: an alternative to unfractionated heparin for anticoagulation in hemodialysis patients.
Vitale C; Berutti S; Bagnis C; Soragna G; Gabella P; Fruttero C; Marangella M
J Nephrol; 2013; 26(1):158-63. PubMed ID: 22419236
[TBL] [Abstract][Full Text] [Related]
39. Anti-factor Xa and activated partial thromboplastin time measurements for heparin monitoring in mechanical circulatory support.
Adatya S; Uriel N; Yarmohammadi H; Holley CT; Feng A; Roy SS; Reding MT; John R; Eckman P; Zantek ND
JACC Heart Fail; 2015 Apr; 3(4):314-22. PubMed ID: 25770404
[TBL] [Abstract][Full Text] [Related]
40. Activated Partial Thromboplastin Time Monitoring of Unfractionated Heparin Therapy: Issues and Recommendations.
Marlar RA; Clement B; Gausman J
Semin Thromb Hemost; 2017 Apr; 43(3):253-260. PubMed ID: 27272964
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
